Swiss National Bank Esperion Therapeutics, Inc. Transaction History

Swiss National Bank

$150 Billion
Q3 2024

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 10, 2023	BUY	$1.46 - $7.3 $52,414 - $262,070	35,900 Added 26.28%	172,500 $274,000
Q4 2022 Feb 08, 2023	BUY	$5.09 - $8.5 $695,294 - $1.16 Million	136,600 New	136,600 $851,000
Q4 2021 Feb 08, 2022	SELL	$4.81 - $11.92 $252,043 - $624,608	-52,400 Closed	0 $0
Q2 2021 Aug 06, 2021	SELL	$19.4 - $28.71 $157,140 - $232,551	-8,100 Reduced 13.39%	52,400 $1.11 Million
Q1 2021 May 07, 2021	BUY	$25.12 - $36.89 $25,120 - $36,890	1,000 Added 1.68%	60,500 $1.7 Million
Q3 2020 Nov 09, 2020	BUY	$31.18 - $52.71 $49,888 - $84,336	1,600 Added 2.76%	59,500 $2.21 Million
Q2 2020 Aug 05, 2020	BUY	$30.04 - $51.31 $306,408 - $523,362	10,200 Added 21.38%	57,900 $2.97 Million
Q1 2020 May 08, 2020	BUY	$27.44 - $73.84 $24,696 - $66,456	900 Added 1.92%	47,700 $1.5 Million
Q4 2019 Feb 06, 2020	BUY	$35.4 - $59.82 $53,100 - $89,730	1,500 Added 3.31%	46,800 $2.79 Million
Q3 2019 Nov 12, 2019	BUY	$34.47 - $47.53 $13,788 - $19,012	400 Added 0.89%	45,300 $1.66 Million
Q2 2019 Aug 02, 2019	BUY	$40.1 - $52.33 $36,090 - $47,097	900 Added 2.05%	44,900 $2.09 Million
Q1 2019 May 10, 2019	BUY	$40.11 - $53.57 $52,143 - $69,641	1,300 Added 3.04%	44,000 $1.77 Million
Q4 2018 Feb 13, 2019	BUY	$36.99 - $59.11 $44,388 - $70,932	1,200 Added 2.89%	42,700 $1.96 Million
Q2 2018 Aug 09, 2018	BUY	$36.2 - $76.4 $202,720 - $427,840	5,600 Added 15.6%	41,500 $1.63 Million
Q1 2018 May 04, 2018	BUY	$65.94 - $80.76 $105,504 - $129,216	1,600 Added 4.66%	35,900 $2.6 Million
Q3 2017 Nov 03, 2017	BUY	$43.8 - $52.77 $1.5 Million - $1.81 Million	34,300	34,300 $1.72 Million

Others Institutions Holding ESPR

# of Institutions

208

Shares Held

128M

Call Options Held

1.67M

Put Options Held

930K

View Full List

About Esperion Therapeutics, Inc.

Ticker ESPR
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 66,551,600
Market Cap $160M
Description
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascul...

More about ESPR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Swiss National Bank, based on Form 13F filings with the SEC.

News

Stay updated on Swiss National Bank with notifications on news.

Account